Format

Send to

Choose Destination
Semin Hematol. 2003 Jan;40(1):50-8.

Imatinib alone and in combination for chronic myeloid leukemia.

Author information

1
Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, Portland, OR 97239, USA.

Abstract

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

PMID:
12563611
DOI:
10.1053/shem.2003.50000
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center